Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production
Abstract
Background/aims Pirfenidone has been recently shown to reduce dimethynitrosamine-induced liver fibrosis in the rat, but no information are available on the effect of this drug on cultured hepatic stellate cells (HSC). Methods HSC proliferation was evaluated by measuring bromodeoxyuridine incorporation; PDGF-receptor autophosphorylation, extracellular signal-regulated kinase (ERK1/2) and pp70(S6K) activation were evaluated by western blot; protein kinase C activation was evaluated by western blot and by ELISA; type I collagen accumulation and alpha1(I) procollagen mRNA expression were evaluated by ELISA and northern blot, respectively. Results Pirfenidone significantly inhibited PDGF-induced HSC proliferation, starting at a concentration of 1 microM, with a maximal effect at 1000 microM, without affecting HSC viability and without inducing apoptosis. The inhibition of PDGF-induced HSC proliferation was associated neither with variations in PDGF-receptor autophosphorylation, or with ERK1/2 and pp70(S6K) activation. On the other hand, pirfenidone was able to inhibit PDGF-induced activation of the Na(+)/H(+) exchanger, which is involved in PDGF-induced HSC proliferation in HSC, with a maximal effect at 1000 microM and inhibited PDGF-induced protein kinase C activation. Pirfenidone 100 and 1000 microM inhibited type I collagen accumulation in the culture medium induced by transforming growth factor(beta1) by 54% and 92%, respectively, as well as TGF(beta1)-induced alpha1(I) procollagen mRNA expression. Results Pirfenidone could be a new candidate for antifibrotic therapy in chronic liver diseases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pirfenidone's main anti-fibrotic efficacy in the liver is mostly attributed to suppression of HSC activation.
“but its main anti-fibrotic efficacy in the liver is mostly attributed to suppression of HSC activation (138, 139).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [138]
Cited by
Sorted by citations
Regulation of PDGF and its receptors in fibrotic diseases
Bonner, J. C. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.006 · Cited by 768 · see citing works
Antifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454 · see citing works
Conte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368 · see citing works
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer
Takai, K., Le, A., Weaver, V. M., & Werb, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12658 · Cited by 207 · see citing works
Stahnke, T., Kowtharapu, B. S., Stachs, O., Schmitz, K.-P., Wurm, J., Wree, A., Guthoff, R. F., & Hovakimyan, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172592 · Cited by 87 · see citing works
Targeting macrophages in liver fibrosis
González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835489 · Cited by 3 · see citing works
- Authors
- Di Sario, A., Bendia, E., Svegliati Baroni, G., Ridolfi, F., Casini, A., Ceni, E., Saccomanno, S., Marzioni, M., Trozzi, L., Sterpetti, P., Taffetani, S., & Benedetti, A.
- Affiliations
- University of Florence (IT)
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2002-11
- Volume
- 37
- Issue
- 5
- Pages
- 584-591
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2029181407
- Cited by
- 138
- References
- 0
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 5 · 2016: 6 · 2015: 6 · 2014: 9 · 2013: 11 · 2012: 6
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- pirfenidone, hepatic stellate cells, stellate cell proliferation, collagen synthesis, liver fibrosis, antifibrotic therapy, PDGF receptor, Na+/H+ exchanger, protein kinase C, ERK1/2, TGF-β1, chronic liver disease
- MeSH terms
- Animals, Antineoplastic Agents, Cell Division, Cells, Cultured, Culture Media, Male, Phosphorylation, Platelet-Derived Growth Factor, Protein Kinase C, Pyridones, RNA, Messenger, Gene Expression, Transforming Growth Factor beta, Rats, Sprague-Dawley, Apoptosis, Sodium-Hydrogen Exchangers, Mitogen-Activated Protein Kinase 1, Receptor, Platelet-Derived Growth Factor beta, Mitogen-Activated Protein Kinases, Hepatocytes, Collagen Type I, Ribosomal Protein S6 Kinases, 70-kDa, Mitogen-Activated Protein Kinase 3, Rats, Transforming Growth Factor beta1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review